BCL2 and Miyoshi myopathy: In the past two decades, there were dramatic advances in the treatment of MM, beginning with the reported use of high-dose melphalan and autologous stem cell transplant in 1996 [28], followed by the introduction of the immunomodulatory drugs [29], the proteasome inhibitors (PI) [30] and BCL-2 inhibitor [31].